NYOH breast cancer survivor on new treatment

Apr 17, 2019

When the FDA recently fast-tracked approval of Tecentriq as the first immunotherapy regimen approved for breast cancer, NYOH patient Cathy Jordan wasn't surprised.

She has been on the treatment since 2015, when it was offered through an earlier phase of a clinical trial at NYOH, led by Dr. Karen Tedesco. Jordan is also a patient of Dr. Rufus Collea

The treatment has allowed Catherine to continue working as a material science engineer at Knolls Atomic Power Labs and watch her daughters grow up and head off to college. 

Cathy and Dr. Tedesco recently joined NewsChannel13's Benita Zahn to discuss the breakthrough treatment for triple negative breast cancer. 

More information about Tecentriq® (atezolizumab) 

Current trials available at NYOH 

Over the past 20 years, New York Oncology Hematology patients have participated in clinical drug trials leading to FDA approval of 41 new cancer therapies. With the largest, most comprehensive clinical research program in the region, NYOH is constantly offering eligible patients opportunities to join promising new trials, right here in the Capital Region. Learn more